In a major development for the healthcare industry and a significant move for a prominent New Jersey-based company, Quest Diagnostics has finalized its acquisition of select laboratory assets from Fresenius Medical Care. This strategic deal positions the Secaucus-based diagnostic giant to become a leading provider of dialysis-related clinical testing services, further cementing its role in managing one of the nation’s most prevalent and costly chronic diseases: chronic kidney disease (CKD).
The transaction, which was completed following an agreement announced in February, involves two key components. First, Quest has acquired the assets of Spectra Laboratories, an FME subsidiary, and will now provide dialysis-related testing to independent clinics that Spectra previously served. Second, under a separate, long-term agreement, Quest will begin providing comprehensive laboratory and water testing services for Fresenius Medical Care’s expansive network of over 3,700 U.S. dialysis centers.
This transition of services to FME’s facilities, which serve more than 200,000 patients annually, is a complex process that will begin this month and is expected to be fully completed by early 2026. According to Quest, the phased rollout will ensure a smooth and seamless integration of services. The acquisition is a win-win for both companies. It allows Fresenius to sharpen its focus on its core business of delivering world-class dialysis care, while leveraging Quest’s clinical expertise and vast national laboratory network.
For patients and providers, the benefits are substantial. Quest’s broad network of laboratories will be able to perform testing for nearby dialysis clinics, significantly reducing transportation time for specimens and, in turn, speeding up the reporting of critical test results. This improved efficiency is vital for managing chronic conditions where timely diagnostic information directly impacts patient care and treatment decisions. Quest also plans to optimize its existing infrastructure by performing this new influx of testing during lower-volume daytime hours, a move that is expected to enhance return on capital for the company.
The acquisition of dialysis-related water testing assets by the end of 2025 further strengthens Quest’s portfolio, adding a new capability that is essential for ensuring patient safety in dialysis treatments. This acquisition demonstrates Quest Diagnostics’ commitment to driving diagnostic innovation and improving health outcomes for a large and vulnerable patient population.
To stay informed about major business developments in the Garden State, be sure to check out our business section.
